AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

Overview of attention for article published in BMC Cancer, August 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 49 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,654 followers.

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer https://t.co/xgrSyV7Nyw https://t.co/oFWvTnenQ2

20 Aug 2021

Reply Repost Favourite

20 Aug 2021

Reply Repost Favourite

New article: AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer https://t.co/5X9xI49Xxj #pancreaticcancer #onco

20 Aug 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.